Strahlentherapie beim Mammakarzinom – Neues und Bewährtes

Die Strahlentherapie ist beim Mammakarzinom ein Bestandteil der multimodalen Therapie. Dieser Beitrag befasst sich mit bewährten Behandlungskonzepten und ergänzt diese mit aktuellen Neuerungen. Die hier dargestellten Themen beziehen sich auf Bestrahlungsindikationen sowie die Bestrahlungskonzepte und -techniken.

Kernaussagen

• Nach brusterhaltender Operation sollte die Bestrahlung der Brust mit einer moderaten Hypofraktionierung erfolgen.

• Der Boost senkt das Lokalrezidivrisiko signifikant, wobei ältere Patientinnen aufgrund des absolut niedrigeren Rückfallrisikos weniger von der Boost-Bestrahlung profitieren; jüngere Patientinnen aufgrund des absolut höheren Rückfallrisikos mehr.

• Bei höherem Risiko (> T1, G3, triplenegativ) ist auch bei postmenopausalen Patientinnen eine Boost-Bestrahlung indiziert.

• Bei älteren Patientinnen mit einem sehr niedrigen Rückfallrisiko kann auf eine Nachbestrahlung nach brusterhaltender Operation unter Inkaufnahme eines etwas erhöhten Lokalrezidivrisikos verzichtet werden.

• Die Bestrahlung der linken Brust sollte in Deep-Inspiration-Breath-hold-Technik durchgeführt werden.

Schlüsselwörter

Mammakarzinom - Strahlentherapie - Fraktionierung - Lymphabflussbestrahlung - Teilbrustbestrahlung

Publikationsverlauf

Artikel online veröffentlicht:
08. Dezember 2021

• Literatur

• 1 Fisher B. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241 DOI: 10.1056/NEJMoa022152. (PMID: 12393820)
• 2 Veronesi U. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-1232 DOI: 10.1056/NEJMoa020989. (PMID: 12393819)
• 3 Clarke M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106 DOI: 10.1016/S0140-6736(05)67887-7. (PMID: 16360786)
• 4 Darby S. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716 DOI: 10.1016/S0140-6736(11)61629-2. (PMID: 22019144)
• 5 Vinh-Hung V. et al. Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiother Oncol 2002; 64: 281-290 DOI: 10.1016/s0167-8140(02)00105-6. (PMID: 12242116)
• 6 EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127-2135
• 7 Matuschek C. et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer – a meta-analysis of randomized trials. Radiation Oncol 2017; 12: 60 DOI: 10.1186/s13014-017-0796-x. (PMID: 28335784)
• 8 Potter R. et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68: 334-340 DOI: 10.1016/j.ijrobp.2006.12.045. (PMID: 17363187)
• 9 Fastner G. et al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. Eur J Cancer 2020; 127: 12-20 DOI: 10.1016/j.ejca.2019.11.024. (PMID: 31962198)
• 10 Fyles AW. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963-970 DOI: 10.1056/NEJMoa040595. (PMID: 15342804)
• 11 Blamey RW. et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013; 49: 2294-2302 DOI: 10.1016/j.ejca.2013.02.031. (PMID: 23523089)
• 12 Hughes KS. et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351: 971-977 DOI: 10.1056/NEJMoa040587. (PMID: 15342805)
• 13 Kunkler IH. et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16: 266-273 DOI: 10.1016/S1470-2045(14)71221-5. (PMID: 25637340)
• 14 Matuschek C. et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol 2017; 12: 60 DOI: 10.1186/s13014-017-0796-x. (PMID: 28335784)
• 15 Sauer R. et al. Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. Cancer 2007; 110: 1187-1194 DOI: 10.1002/cncr.22910. (PMID: 17647249)
• 16 Yarnold J. et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005; 75: 9-17 DOI: 10.1016/j.radonc.2005.01.005. (PMID: 15878095)
• 17 Yarnold J. et al. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys 2011; 79: 1-9 DOI: 10.1016/j.ijrobp.2009.10.074. (PMID: 20471183)
• 18 Swanick CW. et al. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Cancer 2016; 122: 2886-2894 DOI: 10.1002/cncr.30121. (PMID: 27305037)
• 19 Vassilis K. et al. A unique hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions three times per week for early breast cancer: outcomes including local control, acute and late skin toxicity. Breast Cancer 2017; 24: 263-270 DOI: 10.1007/s12282-016-0697-0. (PMID: 27093861)
• 20 Haviland JS. et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-1094 DOI: 10.1016/S1470-2045(13)70386-3. (PMID: 24055415)
• 21 Offersen BV. et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol 2020; 38: 3615-3625 DOI: 10.1200/JCO.20.01363. (PMID: 32910709)
• 22 Franceschini D. et al. Preliminary results of a randomized study on postmenopausal women with early stage breast cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). Clin Breast Cancer 2021; 21: 231-238 DOI: 10.1016/j.clbc.2020.09.004. (PMID: 33121891)
• 23 AWMF. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie 2012. Version 4.4. Im Internet (Stand: Juni 2021): https://www.awmf.org/uploads/tx_szleitlinien/032–045OLl_S3_Mammakarzinom_2021–07.pdf
• 24 Poortmans PM. et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 2020; 21: 1602-1610 DOI: 10.1016/S1470-2045(20)30472-1. (PMID: 33152277)
• 25 Budach W. et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol 2015; 10: 258 DOI: 10.1186/s13014-015-0568-4. (PMID: 26691175)
• 26 Dodwell D, Taylor C, McGale P. et al. Regional lymph node irradiation in early stage breast cancer. An EBCTCG meta-analysis of 13000 women in 14 trials. Cancer Res 2019; 79: G54-02 DOI: 10.1158/1538-7445.
• 27 Haviland JS. et al. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol 2018; 126: 155-162 DOI: 10.1016/j.radonc.2017.10.033. (PMID: 29153463)
• 28 Bellefqih S. et al. Hypofractionated regional nodal irradiation for women with node-positive breast cancer. Int J Radiat Oncol Biol Phys 2017; 97: 563-570 DOI: 10.1016/j.ijrobp.2016.11.010. (PMID: 28126305)
• 29 Guenzi M. et al. Hypofractionated irradiation of infra-supraclavicular lymph nodes after axillary dissection in patients with breast cancer post-conservative surgery: impact on late toxicity. Radiat Oncol 2015; 10: 177 DOI: 10.1186/s13014-015-0480-y. (PMID: 26289040)
• 30 Brunt AM. et al. Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020; 38: 3261-3272 DOI: 10.1200/JCO.19.02750. (PMID: 32663119)
• 31 Bartelink H. et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol 2007; 25: 3259-3265 DOI: 10.1200/JCO.2007.11.4991. (PMID: 17577015)
• 32 Bartelink H. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16: 47-56 DOI: 10.1016/S1470-2045(14)71156-8. (PMID: 25500422)
• 33 Fastner G. et al. IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol 2013; 108: 279-286 DOI: 10.1016/j.radonc.2013.05.031. (PMID: 23830467)
• 34 Fastner G. et al. IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up. Int J Cancer 2015; 136: 1193-1201 DOI: 10.1002/ijc.29064. (PMID: 24995409)
• 35 Fastner G. et al. Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery. Strahlenther Onkol 2016; 192: 1-7 DOI: 10.1007/s00066-015-0895-2. (PMID: 26403912)
• 36 Fastner G. et al. Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiother Oncol 2020; 146: 136-142 DOI: 10.1016/j.radonc.2020.02.001. (PMID: 32151790)
• 37 Vaidya JS. et al. Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. Int J Radiat Oncol Biol Phys 2006; 66: 1335-1338 DOI: 10.1016/j.ijrobp.2006.07.1378. (PMID: 17084562)
• 38 Niehoff P. et al. Clinical experience with the MammoSite radiation therapy system for brachytherapy of breast cancer: results from an international phase II trial. Radiother Oncol 2006; 79: 316-320 DOI: 10.1016/j.radonc.2006.05.010. (PMID: 16780977)
• 39 Major T. et al. Dosimetric comparisons between high dose rate interstitial and MammoSite balloon brachytherapy for breast cancer. Radiother Oncol 2006; 79: 321-328 DOI: 10.1016/j.radonc.2006.05.005. (PMID: 16730085)
• 40 Polgar C. et al. The role of high-dose-rate brachytherapy boost in breast-conserving therapy: Long-term results of the Hungarian National Institute of Oncology. Rep Pract Oncol Radiother 2010; 15: 1-7 DOI: 10.1016/j.rpor.2010.01.002. (PMID: 24376915)
• 41 Krug D. et al. Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial. Strahlenther Onkol 2021; 197: 48-55 DOI: 10.1007/s00066-020-01689-7. (PMID: 33001241)
• 42 Krug D. et al. Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiat Oncol 2020; 15: 235 DOI: 10.1186/s13014-020-01652-x. (PMID: 33050920)
• 43 Strnad V. et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387: 229-238 DOI: 10.1016/S0140-6736(15)00471-7. (PMID: 26494415)
• 44 Ott OJ. et al. GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Oncol 2016; 120: 119-123 DOI: 10.1016/j.radonc.2016.06.019. (PMID: 27422584)
• 45 Vaidya JS. et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91-102 DOI: 10.1016/S0140-6736(10)60837-9. (PMID: 20570343)
• 46 Haussmann J. et al. No difference in overall survival and non-breast cancer deaths after partial breast radiotherapy compared to whole breast radiotherapy – A meta-analysis of randomized trials. Cancers (Basel) 2020; 12 DOI: 10.3390/cancers12082309. (PMID: 32824414)
• 47 Vicini FA. et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019; 394: 2155-2164 DOI: 10.1016/S0140-6736(19)32514-0. (PMID: 31813636)
• 48 Whelan TJ. et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019; 394: 2165-2172 DOI: 10.1016/S0140-6736(19)32515-2. (PMID: 31813635)
• 49 Meattini I. et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol 2020; 38: 4175-4183 DOI: 10.1200/JCO.20.00650. (PMID: 32840419)
• 50 Veronesi U. et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269-1277 DOI: 10.1016/S1470-2045(13)70497-2. (PMID: 24225155)
• 51 Vaidya JS. et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-613 DOI: 10.1016/S0140-6736(13)61950-9. (PMID: 24224997)
• 52 Vaidya JS. et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. Br Med J 2020; 370: m2836
• 53 Coles CE. et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390: 1048-1060 DOI: 10.1016/S0140-6736(17)31145-5. (PMID: 28779963)
• 54 Polgar C. et al. Breast-conserving surgery followed by partial or whole breast irradiation: Twenty-year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021; 109: 998-1006 DOI: 10.1016/j.ijrobp.2020.11.006. (PMID: 33186620)
• 55 Offersen BN. et al. Partial breast radiotherapy after breast conservation for breast cancer: Early results from the randomised DBCG PBI trial. Radiother Oncol 2017; 123: S163-S164
• 56 Piroth MD. et al. Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?. Strahlenther Onkol 2021; 197: 1-7 DOI: 10.1007/s00066-020-01667-z. (PMID: 32737515)
• 57 Strnad V. et al. DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol 2020; 196: 749-763 DOI: 10.1007/s00066-020-01613-z. (PMID: 32350554)
• 58 Forster T. et al. Fatigue following radiotherapy of low-risk early breast cancer - a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). Radiat Oncol 2020; 15: 134 DOI: 10.1186/s13014-020-01581-9. (PMID: 32487184)
• 59 Choi KH. et al. Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15–03. Radiother Oncol 2020; 154: 179-186 DOI: 10.1016/j.radonc.2020.09.043. (PMID: 32980384)
• 60 Freedman GM. et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol 2006; 29: 66-70 DOI: 10.1097/01.coc.0000197661.09628.03. (PMID: 16462506)
• 61 Saibishkumar EP. et al. Skin-sparing radiation using intensity-modulated radiotherapy after conservative surgery in early-stage breast cancer: A planning study. Int J Radiat Oncol Biol Phys 2007; DOI: 10.1016/j.ijrobp.2007.06.049. (PMID: 17881140)
• 62 Borst GR. et al. Clinical results of image-guided deep inspiration breath hold breast irradiation. Int J Radiat Oncol Biol Phys 2010; 78: 1345-1351 DOI: 10.1016/j.ijrobp.2009.10.006. (PMID: 20207496)
• 63 Bergom C. et al. Deep inspiration breath hold: Techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol 2018; 8: 87 DOI: 10.3389/fonc.2018.00087. (PMID: 29670854)
• 64 Cooper S. et al. Respiratory gating: Using deep inspiration breath hold radiation therapy to treat left breast cancer. J Med Imaging Radiat Sci 2008; 39: 192-197 DOI: 10.1016/j.jmir.2008.08.001. (PMID: 31051780)
• 65 Remouchamps VM. et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2003; 55: 392-406 DOI: 10.1016/s0360-3016(02)04143-3. (PMID: 12527053)
• 66 Sixel KE. et al. Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys 2001; 49: 199-204 DOI: 10.1016/s0360-3016(00)01455-3. (PMID: 11163515)
• 67 Zurl B. et al. Quantitative assessment of irradiated lung volume and lung mass in breast cancer patients treated with tangential fields in combination with deep inspiration breath hold (DIBH). Strahlenther Onkol 2010; 186: 157-162 DOI: 10.1007/s00066-010-2064-y. (PMID: 20165819)
• 68 Rice L. et al. An effective deep-inspiration breath-hold radiotherapy technique for left-breast cancer: impact of post-mastectomy treatment, nodal coverage, and dose schedule on organs at risk. Breast Cancer (Dove Med Press) 2017; 9: 437-446 DOI: 10.2147/BCTT.S130090. (PMID: 28652810)